Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Core Insights - Black Diamond Therapeutics, Inc. released topline data from its Phase 2 trial of silevertinib for frontline non-small cell lung cancer patients with non-classical EGFR mutations [1] Trial Results - All patients were treated with a daily oral dose of 200mg of silevertinib, with a median follow-up time of 7.2 months as of the data cutoff on November 3, 2025 [2] - The trial reported 25 confirmed partial responses and one confirmed complete response, resulting in a 60% Objective Response Rate (ORR) [6] - The Central Nervous System (CNS) ORR was 86%, and the disease control rate (DCR) was 91% [6] - No new safety signals were observed, with common adverse events including rash, stomatitis, diarrhea, and paronychia [2] Future Plans - The company plans to present updated results, including Duration of Response (DOR) and Progression-free Survival (PFS) data, at a medical meeting in the second quarter of 2026 [3] - Black Diamond intends to initiate a randomized Phase 2 trial in newly diagnosed glioblastoma patients in the first half of 2026, expecting to enroll approximately 150 patients [4] Financial Position - As of September 30, 2025, the company reported cash, cash equivalents, and investments of approximately $135.5 million, which is expected to fund operations and capital expenditures into the second half of 2028 [7] Stock Performance - BDTX stock experienced a decline of 23.77%, trading at $2.62 at the time of publication [4]